The Business Research Company’s report on the Fibrate Drugs Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the key drivers behind the fibrate drugs market’s growth in recent years?
The increased incidence of cardiac diseases is expected to propel the growth of the fibrate drug market going forward. Cardiac diseases encompass a range of conditions affecting both the heart and the blood vessels. It includes coronary heart disease, congenital heart disease, and others. Fibrates are used as a treatment to prevent further heart attacks and strokes in people who already have the condition of their circulatory system, resulting in driving the fibrate drug market. For instance, in May 2024, according to the Singapore Heart Foundation (SHF), a Singapore-based non-profit organization, ischemic heart diseases resulted in 5,302 deaths, showing a slight increase from 5,290 deaths in 2022. Additionally, the total number of deaths due to hypertensive diseases accounted for 3.7% in 2022, up from 3.4% in 2021. Therefore, the increased incidence of cardiac diseases is driving the growth of the fibrate drugs market.
Access Your Free Sample of the Global Fibrate Drugs Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11932&type=smp
How does the future projection of the fibrate drugs market size compare to its historical growth?
The fibrate drugs market size has grown steadily in recent years. It will grow from $3.49 billion in 2024 to $3.62 billion in 2025 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to emergence of lipid management, cholesterol management focus, clinical research and trials, cardiovascular risk reduction, combination therapies
The fibrate drugs market size is expected to see strong growth in the next few years. It will grow to $4.81 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to evolving treatment guidelines, focus on residual risk, precision medicine advancements, innovation in drug delivery. Major trends in the forecast period include alternative formulations, telemedicine integration, fibrates in high-risk groups, targeting triglyceride levels, focus on hdl raising .
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=11932&type=smp
Which key players are shaping the future of the fibrate drugs market?
Major companies operating in the fibrate drugs market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Bristol-Myers Squibb Co, Abbott Laboratories, AstraZeneca plc, GlaxoSmithKline Plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Co Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Inc., Zydus Lifesciences Ltd, Lupin Limited, Glenmark Pharmaceuticals, Torrent Pharmaceuticals Ltd., Natco Pharma, Hetero Drugs Ltd
What trends will propel the growth and evolution of the fibrate drugs market?
Major companies operating in the fibrate drugs market are focused on developing innovative solutions such as fixed-dose combinations to sustain their position in the market. A fixed-dose combination refers to a pharmaceutical formulation that includes two or more active ingredients in a single dosage form, allowing for more convenient administration and potentially improved therapeutic outcomes. For instance, in May 2023, Intercept Pharmaceuticals Inc., a US-based biopharmaceutical company, received the U.S. Food and Drug Administration (FDA) approval for orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate. This combination, a peroxisome proliferator-activated receptor (PPAR) agonist, is being explored for the potential treatment of individuals with primary biliary cholangitis (PBC). OCA, a farnesoid X receptor (FXR) agonist, is marketed by Intercept as Ocaliva in the United States for PBC treatment, while bezafibrate, a pan-PPAR agonist, is not currently approved in the United States for any indication.
Which regions are expected to become dominant players in the fibrate drugs market?
North America was the largest region in the fibrate drugs market in 2024. The regions covered in the fibrate drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/fibrate-drugs-global-market-report
What are the emerging key segments in the fibrate drugs market, and how are they evolving?
The fibrate drugs market covered in this report is segmented –
1) By Drug Type: Clofibrate, Fenofibrates, Fenofibric Acids, Gemfibrozil, Other Drugs
2) By Indication: Hypercholesterolemia, Heart Attacks, Other Indications
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Clofibrate: Standard Clofibrate, Combination Products
2) By Fenofibrates: Fenofibrate Capsules, Fenofibrate Tablets, Combination Products
3) By Fenofibric Acids: Fenofibric Acid Capsules, Combination Products
4) By Gemfibrozil: Standard Gemfibrozil, Combination Products
5) By Other Drugs: Other Fibrate Formulations, Emerging Fibrate Drugs
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11932
What defines the structure and scope of the fibrate drugs market?
Fibrate drugs are prescription drugs that reduce triglyceride levels and raise high-density lipoprotein (HDL) cholesterol levels. Fibrate drugs are used to treat hypercholesterolemia or mixed dyslipidemia.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
